Match Document Document Title
7402653 Biologically active peptides  
Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced...
7399826 Peptide for promoting healing of fractures  
The peptide for promoting healing of fractures is a 13-amino acid peptide which is sequenced and synthesized in the laboratory. The peptide SHMSP has the sequence represented by the formula...
7396815 Cosmetic or pharmaceutical composition containing peptides  
A cosmetic and/or dermatological and/or pharmaceutical composition includes, as the active ingredient, at least one peptide with sequence X 1 -Y-Phe-Thr-X 2 -Ala-Thr-Z-Ile-X 3 -Leu-X 4 -Phe-Leu-X 5...
7393834 LHRH-antagonists in the treatment of fertility disorders  
A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing...
7390787 Compositions and methods for treating infections using analogues of indolicidin  
Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues...
7381704 Methods for use of short bioactive peptides  
Short bioactive peptides containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological...
7381706 Gonadotropin-releasing hormone, precursor peptides thereof and genes encoding the same  
A novel peptide found as gonadotropin-releasing hormone (GnRH) in octopuses, a member of mollusks. The structure and the activities of the peptide have been unraveled. The peptide finds use as a...
7378396 Therapeutic agents and methods for cardiovascular disease  
The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO)...
7375083 Pharmaceutical compositions for prevention of overdose or abuse  
The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause...
7368119 Compositions and methods for WT1 specific immunotherapy  
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
7368429 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients  
Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire...
7368430 Selective inhibitors of nuclear factor-κB activation and uses thereof  
The present invention provides cell permeable NF-κB inhibitors consist of a polypeptide derived from the p65 subunit of NF-κB and a protein transduction domain derived from antennapedia third...
7368127 Biomedical devices with peptide containing coatings  
Biomedical devices with stable peptide coatings are provided. The coatings are formed by incorporating at least one latent reactive component into the reactive mixture, forming a medical device...
7364887 Use of PAK inhibitor for the treatment of a joint disease  
The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain...
7345022 Anti-fibril peptides  
Novel peptides are disclosed that may be used as inhibitors of amyloidogenesis, as suppressors of amyloid toxicity, and as therapeutic agents for amyloid-associated diseases such as Alzheimer's...
7341994 GD3-mimetic peptides  
GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of...
7338932 Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments  
Attachment of O-glycans to proteins is controlled by a large family of homologous polypeptide GalNAc-transferases. Polypeptide GalNAc-transferases contain a C-terminal sequence with similarity to...
7326688 Analogs of gastric inhibitory polypeptide and their use of treatment for diabetes  
The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion...
7326682 Conotoxin peptides  
The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such...
7326686 Compounds and methods for regulating cell adhesion  
Methods for using modulating agents to enhance or inhibit cadherin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. In particular, the modulating agents may be...
7319090 Methods of treating cerebral ischemia  
The present invention provides methods of treating cerebral ischemia in mammals comprising inducing hypothermia in a mammal before, during, or following cerebral ischemia in the mammal. The...
7317003 Small peptides having anti-angiogenic and endothelial cell inhibition activity  
The present invention provides peptides having potent anti-angiogenic activity and endothelial cell proliferation inhibition activity. The peptides can be administered as pharmaceutical...
7314864 Humanin, a polypeptide suppressing neuronal death  
The present invention provides polypeptides that suppresses neuronal death associated with Alzheimer's disease. Using a neuronal cell system, wherein the expression of familial Alzheimer's disease...
7314865 Compositions and methods for promoting lipid mobilization in humans  
The invention provides methods of using polypeptide compounds based on the structures of insect peptides of the adipokinetic hormone family to mobilize lipids in humans. The compositions and...
7312193 Calcium phosphopeptide complexes  
Phosphopeptides containing the Ser(P) cluster sequence motif Ser(P)-Ser(P)-Ser(P)-Glu-Glu- can stabilize their own weight in amorphous calcium phosphate (ACP) [Ca 3 (PO 4 ) 1.87 (HPO 4 ) 0.2 xH 2...
7304035 Stimulation of bone growth with thrombin peptide derivatives  
Disclosed is a method of stimulating bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of...
7304036 Methods and compositions for the treatment of gastrointestinal disorders  
The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional...
7294615 Compounds that associate on the intermolecular level and aggregate bodies that contain them  
Compound of the general formula (I) X(B) m (I) wherein X is an m-valent...
7291599 Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases  
The invention relates to a process for the treatment of neurodegenerative diseases wherein mis-folded proteins accumulate in characteristic lesions and contribute substantially to a pathogenesis...
7285525 Suppression of immune response via inhibition of cathepsin S  
Methods and products for suppressing a class II MI-IC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by...
7285264 Peptide-based body surface coloring reagents  
Peptides have been identified that bind with high affinity to body surfaces, such as, hair, skin, nails, teeth, gums, and oral cavity surfaces. Diblock and triblock peptide-based body surface...
7285524 Allo and auto-reactive T-cell epitopes  
The present invention relates to a pharmaceutical composition for the prevention of alloimmunization of a subject or the immunosuppression of a response elicited by alloimmunization of a subject or...
7285535 Toll/interleukin-1 receptor adapter protein (TIRAP)  
TIRAP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TIRAP polypeptides and...
7282214 Biomedical devices with antimicrobial coatings  
Biomedical devices with antimicrobial coatings are provided. One or more surfaces of the device are coated with a cationic peptide, cationic proteins, or mixtures thereof to impart antimicrobial...
7276482 Peptide and peptide mimetic derivatives with integrin-inhibitors properties II  
The invention relates to compounds of formula (I) B-Q-X 1 , wherein B is a bioactive, cell adhesive mediating molecule, selected from the group (i) and...
7276251 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid  
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in...
7273846 Selective melanin-concentrating hormone type-1 receptor agonists  
The present invention features truncated hMCH analogs selectively active at MCH-1R over MCH-2R. Using amino acid numbering provided in hMCH, the featured analogs contain an X 6 which is either a...
7268155 Photosensitizer conjugates for pathogen targeting  
Conjugate molecules which include photosensitizer compositions conjugated to non-antibody non-affinity pair targeting moieties and methods of making and using such conjugates are described.
7265088 Method and compositions for altering mucus secretion  
Methods and compounds for increasing or decreasing mucus secretion in subjects, and particularly mucus secretion in the airways, are described. Methods of screening compounds for the ability to...
7262163 Short amphipathic peptides with activity against bacteria and intracellular pathogens  
“Minimalist” antimicrobial peptides are disclosed based on 50 to 80% α,α-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar...
7259137 Peptides and related molecules that bind to TALL-1  
The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz 2 Lz 4 ...
7258996 Metalloproteinase inhibitory agent  
The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent of casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The...
7255861 Preparations for inducing immunotolerance and uses therefor  
The present invention provides isolated peptides relating to the autoimmune diseases pemphigus vulgaris and multiple sclerosis. The peptides relating to pemphigus vulgaris are self epitopes and...
7252829 HLA binding peptides and their uses  
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles...
7244708 Inhibitors of memapsin 2 and use thereof  
Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been...
7244702 Purified Cys moiety for iron reductase, and method for obtaining and using same  
The invention comprises a preparation of X-S-Cys-X, moiety, BRAUNMYCIN Î>>, where X maybe naturally linked peptide or glycan residues essential for iron-reductase activity, as well as...
7244710 Treatment of ophthalmic infections using antimicrobial peptides  
The present invention discloses a method of treating an ophthalmic infection by administering to a vertebrate inflicted with the ophthalmic infection an ophthalmologically effective amount of an...
7241740 Peptides as solubilizing excipients for transforming growth factor beta proteins  
The present invention relates to compositions comprising excipients or solubilizing agents for proteins. The invention relates to the discovery that a peptide derived from the N-terminus extension...
7238669 Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae  
Whole cell phage-display techniques were used to identify several peptides that bound preferentially to a non-typeable strain of Haemophilus influenzae . These peptides were able to inhibit growth...
7238671 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions  
The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or...